<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36518246</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>ADAR1-dependent editing regulates human &#x3b2;&#xa0;cell transcriptome diversity during inflammation.</ArticleTitle><Pagination><StartPage>1058345</StartPage><MedlinePgn>1058345</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1058345</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2022.1058345</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Enterovirus infection has long been suspected as a possible trigger for type 1 diabetes. Upon infection, viral double-stranded RNA (dsRNA) is recognized by membrane and cytosolic sensors that orchestrate type I interferon signaling and the recruitment of innate immune cells to the pancreatic islets. In this context, adenosine deaminase acting on RNA 1 (ADAR1) editing plays an important role in dampening the immune response by inducing adenosine mispairing, destabilizing the RNA duplexes and thus preventing excessive immune activation.</AbstractText><AbstractText Label="METHODS">Using high-throughput RNA sequencing data from human islets and EndoC-&#x3b2;H1 cells exposed to IFN&#x3b1; or IFN&#x3b3;/IL1&#x3b2;, we evaluated the role of ADAR1 in human pancreatic &#x3b2; cells and determined the impact of the type 1 diabetes pathophysiological environment on ADAR1-dependent RNA editing.</AbstractText><AbstractText Label="RESULTS">We show that both IFN&#x3b1; and IFN&#x3b3;/IL1&#x3b2; stimulation promote ADAR1 expression and increase the A-to-I RNA editing of Alu-Containing mRNAs in EndoC-&#x3b2;H1 cells as well as in primary human islets.</AbstractText><AbstractText Label="DISCUSSION">We demonstrate that ADAR1 overexpression inhibits type I interferon response signaling, while ADAR1 silencing potentiates IFN&#x3b1; effects. In addition, ADAR1 overexpression triggers the generation of alternatively spliced mRNAs, highlighting a novel role for ADAR1 as a regulator of the &#x3b2;&#xa0;cell transcriptome under inflammatory conditions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Szymczak, Cohen-Fultheim, Thomaidou, de Brach&#xe8;ne, Castela, Colli, Marchetti, Levanon, Eizirik and Zaldumbide.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szymczak</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ULB Center for Diabetes Research, Medical Faculty, Universit&#xe9; Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen-Fultheim</LastName><ForeName>Roni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomaidou</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Brach&#xe8;ne</LastName><ForeName>Alexandra Coomans</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>ULB Center for Diabetes Research, Medical Faculty, Universit&#xe9; Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castela</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ULB Center for Diabetes Research, Medical Faculty, Universit&#xe9; Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colli</LastName><ForeName>Maikel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ULB Center for Diabetes Research, Medical Faculty, Universit&#xe9; Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levanon</LastName><ForeName>Erez</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eizirik</LastName><ForeName>Decio</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ULB Center for Diabetes Research, Medical Faculty, Universit&#xe9; Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaldumbide</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 DK127786</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.5.4.4</RegistryNumber><NameOfSubstance UI="D000243">Adenosine Deaminase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.37</RegistryNumber><NameOfSubstance UI="C000595356">ADAR protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000243" MajorTopicYN="Y">Adenosine Deaminase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050417" MajorTopicYN="Y">Insulin-Secreting Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012330" MajorTopicYN="N">RNA, Double-Stranded</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="Y">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA editing</Keyword><Keyword MajorTopicYN="N">T1D (type 1 diabetes)</Keyword><Keyword MajorTopicYN="N">beta cell (&#x3b2; cell)</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">transcriptome</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>2</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36518246</ArticleId><ArticleId IdType="pmc">PMC9742459</ArticleId><ArticleId IdType="doi">10.3389/fendo.2022.1058345</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Szymczak F, Colli ML, Mamula MJ, Evans-Molina C, Eizirik DL. Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. Sci Adv (2021) 7(2):1&#x2013;11. doi:&#xa0;10.1126/sciadv.abd7600</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd7600</ArticleId><ArticleId IdType="pmc">PMC7787485</ArticleId><ArticleId IdType="pubmed">33523973</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: Mda5 in antiviral immunity and autoinflammation. Trends Microbiol (2019) 27(1):75&#x2013;85. doi:&#xa0;10.1016/j.tim.2018.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2018.08.007</ArticleId><ArticleId IdType="pmc">PMC6319154</ArticleId><ArticleId IdType="pubmed">30201512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, van den Hoogen BG, Haagmans BL. Adar1: &#x201c;Editor-in-Chief&#x201d; of cytoplasmic innate immunity. Front Immunol (2019) 10:1763. doi:&#xa0;10.3389/fimmu.2019.01763</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01763</ArticleId><ArticleId IdType="pmc">PMC6669771</ArticleId><ArticleId IdType="pubmed">31404141</ArticleId></ArticleIdList></Reference><Reference><Citation>Heraud-Farlow JE, Walkley CR. The role of rna editing by Adar1 in prevention of innate immune sensing of self-rna. J Mol Med (Berl) (2016) 94(10):1095&#x2013;102. doi:&#xa0;10.1007/s00109-016-1416-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-016-1416-1</ArticleId><ArticleId IdType="pubmed">27044320</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et al. . Mutations in Adar1 cause aicardi-goutieres syndrome associated with a type I interferon signature. Nat Genet (2012) 44(11):1243&#x2013;8. doi:&#xa0;10.1038/ng.2414</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2414</ArticleId><ArticleId IdType="pmc">PMC4154508</ArticleId><ArticleId IdType="pubmed">23001123</ArticleId></ArticleIdList></Reference><Reference><Citation>Song IH, Kim YA, Heo SH, Park IA, Lee M, Bang WS, et al. . Adar1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer. Tumour Biol (2017) 39(10):1010428317734816. doi:&#xa0;10.1177/1010428317734816</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428317734816</ArticleId><ArticleId IdType="pubmed">29022489</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth SH, Danan-Gotthold M, Ben-Izhak M, Rechavi G, Cohen CJ, Louzoun Y, et al. . Increased rna editing may provide a source for autoantigens in systemic lupus erythematosus. Cell Rep (2018) 23(1):50&#x2013;7. doi:&#xa0;10.1016/j.celrep.2018.03.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.03.036</ArticleId><ArticleId IdType="pmc">PMC5905401</ArticleId><ArticleId IdType="pubmed">29617672</ArticleId></ArticleIdList></Reference><Reference><Citation>Eizirik DL, Pasquali L, Cnop M. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: Different pathways to failure. Nat Rev Endocrinol (2020) 16(7):349&#x2013;62. doi:&#xa0;10.1038/s41574-020-0355-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-0355-7</ArticleId><ArticleId IdType="pubmed">32398822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallone R, Eizirik DL. Presumption of innocence for beta cells: Why are they vulnerable autoimmune targets in type 1 diabetes? Diabetologia (2020) 63(10):1999&#x2013;2006. doi:&#xa0;10.1007/s00125-020-05176-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-020-05176-7</ArticleId><ArticleId IdType="pubmed">32894310</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H, Guyer P, Ettinger RA, James EA. Non-genetically encoded epitopes are relevant targets in autoimmune diabetes. Biomedicines (2021) 9(2):1&#x2013;13. doi:&#xa0;10.3390/biomedicines9020202</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9020202</ArticleId><ArticleId IdType="pmc">PMC7922826</ArticleId><ArticleId IdType="pubmed">33671312</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Calvo T, Johnson JD, Overbergh L, Dunne JL. Neoepitopes in type 1 diabetes: Etiological insights, biomarkers and therapeutic targets. Front Immunol (2021) 12:667989. doi:&#xa0;10.3389/fimmu.2021.667989</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.667989</ArticleId><ArticleId IdType="pmc">PMC8089389</ArticleId><ArticleId IdType="pubmed">33953728</ArticleId></ArticleIdList></Reference><Reference><Citation>Christofi T, Zaravinos A. Rna editing in the forefront of epitranscriptomics and human health. J Transl Med (2019) 17(1):319. doi:&#xa0;10.1186/s12967-019-2071-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-2071-4</ArticleId><ArticleId IdType="pmc">PMC6757416</ArticleId><ArticleId IdType="pubmed">31547885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang SJ, Shen H, An O, Hong H, Li J, Song Y, et al. . Cis- and trans-regulations of pre-mrna splicing by rna editing enzymes influence cancer development. Nat Commun (2020) 11(1):799. doi:&#xa0;10.1038/s41467-020-14621-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14621-5</ArticleId><ArticleId IdType="pmc">PMC7005744</ArticleId><ArticleId IdType="pubmed">32034135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Wei Z, Zhang L, Yang Z, Liu Q. Systematically characterizing a-to-I rna editing neoantigens in cancer. Front Oncol (2020) 10:593989. doi:&#xa0;10.3389/fonc.2020.593989</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.593989</ArticleId><ArticleId IdType="pmc">PMC7758481</ArticleId><ArticleId IdType="pubmed">33363023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, et al. . Conventional and neo-antigenic peptides presented by beta cells are targeted by circulating naive Cd8+ T cells in type 1 diabetic and healthy donors. Cell Metab (2018) 28(6):946&#x2013;60.e6. doi:&#xa0;10.1016/j.cmet.2018.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.07.007</ArticleId><ArticleId IdType="pubmed">30078552</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhbari P, Richardson SJ, Morgan NG. Type 1 diabetes: Interferons and the aftermath of pancreatic beta-cell enteroviral infection. Microorganisms (2020) 8(9):1&#x2013;18. doi:&#xa0;10.3390/microorganisms8091419</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8091419</ArticleId><ArticleId IdType="pmc">PMC7565444</ArticleId><ArticleId IdType="pubmed">32942706</ArticleId></ArticleIdList></Reference><Reference><Citation>Colli ML, Szymczak F, Eizirik DL. Molecular footprints of the immune assault on pancreatic beta cells in type 1 diabetes. Front Endocrinol (Lausanne) (2020) 11:568446. doi:&#xa0;10.3389/fendo.2020.568446</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.568446</ArticleId><ArticleId IdType="pmc">PMC7522353</ArticleId><ArticleId IdType="pubmed">33042023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M, Czernichow P, et al. . A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion. J Clin Invest (2011) 121(9):3589&#x2013;97. doi:&#xa0;10.1172/JCI58447</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI58447</ArticleId><ArticleId IdType="pmc">PMC3163974</ArticleId><ArticleId IdType="pubmed">21865645</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen KR, Streett DA, Gerritsen AT, Hunter SS, Settles ML. . super deduper, fast pcr duplicate detection in fastq files. In: Proceedings of the 6th ACM conference on bioinformatics, computational biology and health informatics;. Atlanta, Georgia: Association for Computing Machinery; (2015). p. 491&#x2013;2.</Citation></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. . Star: Ultrafast universal rna-seq aligner. Bioinformatics (2013) 29(1):15&#x2013;21. doi:&#xa0;10.1093/bioinformatics/bts635</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth SH, Levanon EY, Eisenberg E. Genome-wide quantification of adar adenosine-to-Inosine rna editing activity. Nat Methods (2019) 16(11):1131&#x2013;8. doi:&#xa0;10.1038/s41592-019-0610-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0610-9</ArticleId><ArticleId IdType="pubmed">31636457</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Anders S, Kim V, Huber W. Rna-seq workflow: Gene-level exploratory analysis and differential expression. F1000Res (2015) 4:1070. doi:&#xa0;10.12688/f1000research.7035.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.7035.1</ArticleId><ArticleId IdType="pmc">PMC4670015</ArticleId><ArticleId IdType="pubmed">26674615</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI, Robinson MD. Differential analyses for rna-seq: Transcript-level estimates improve gene-level inferences. F1000Res (2015) 4:1521. doi:&#xa0;10.12688/f1000research.7563.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.7563.2</ArticleId><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhou Y, Chen Y, Gu J. Fastp: An ultra-fast all-in-One fastq preprocessor. Bioinformatics (2018) 34(17):i884&#x2013;i90. doi:&#xa0;10.1093/bioinformatics/bty560</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty560</ArticleId><ArticleId IdType="pmc">PMC6129281</ArticleId><ArticleId IdType="pubmed">30423086</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods (2017) 14(4):417&#x2013;9. doi:&#xa0;10.1038/nmeth.4197</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4197</ArticleId><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for rna-seq data with Deseq2. Genome Biol (2014) 15(12):550. doi:&#xa0;10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv (2021), 060012. doi:&#xa0;10.1101/060012</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY. Clusterprofiler: An r package for comparing biological themes among gene clusters. OMICS (2012) 16(5):284&#x2013;7. doi:&#xa0;10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlotti F, Bazuine M, Kekarainen T, Seppen J, Pognonec P, Maassen JA, et al. . Lentiviral vectors efficiently transduce quiescent mature 3t3-L1 adipocytes. Mol Ther (2004) 9(2):209&#x2013;17. doi:&#xa0;10.1016/j.ymthe.2003.11.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2003.11.021</ArticleId><ArticleId IdType="pubmed">14759805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun (2018) 94:7&#x2013;15. doi:&#xa0;10.1016/j.jaut.2018.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.08.003</ArticleId><ArticleId IdType="pmc">PMC6235162</ArticleId><ArticleId IdType="pubmed">30115527</ArticleId></ArticleIdList></Reference><Reference><Citation>von Herrath MG, Oldstone MB. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med (1997) 185(3):531&#x2013;9. doi:&#xa0;10.1084/jem.185.3.531</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.185.3.531</ArticleId><ArticleId IdType="pmc">PMC2196037</ArticleId><ArticleId IdType="pubmed">9053453</ArticleId></ArticleIdList></Reference><Reference><Citation>Colli ML, Ramos-Rodriguez M, Nakayasu ES, Alvelos MI, Lopes M, Hill JLE, et al. . An integrated multi-omics approach identifies the landscape of interferon-Alpha-Mediated responses of human pancreatic beta cells. Nat Commun (2020) 11(1):2584. doi:&#xa0;10.1038/s41467-020-16327-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16327-0</ArticleId><ArticleId IdType="pmc">PMC7244579</ArticleId><ArticleId IdType="pubmed">32444635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Rodriguez M, Raurell-Vila H, Colli ML, Alvelos MI, Subirana-Granes M, Juan-Mateu J, et al. . The impact of proinflammatory cytokines on the beta-cell regulatory landscape provides insights into the genetics of type 1 diabetes. Nat Genet (2019) 51(11):1588&#x2013;95. doi:&#xa0;10.1038/s41588-019-0524-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0524-6</ArticleId><ArticleId IdType="pmc">PMC7040466</ArticleId><ArticleId IdType="pubmed">31676868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazak L, Haviv A, Barak M, Jacob-Hirsch J, Deng P, Zhang R, et al. . A-to-I rna editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res (2014) 24(3):365&#x2013;76. doi:&#xa0;10.1101/gr.164749.113</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.164749.113</ArticleId><ArticleId IdType="pmc">PMC3941102</ArticleId><ArticleId IdType="pubmed">24347612</ArticleId></ArticleIdList></Reference><Reference><Citation>Porath HT, Carmi S, Levanon EY. A genome-wide map of hyper-edited rna reveals numerous new sites. Nat Commun (2014) 5:4726. doi:&#xa0;10.1038/ncomms5726</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5726</ArticleId><ArticleId IdType="pmc">PMC4365171</ArticleId><ArticleId IdType="pubmed">25158696</ArticleId></ArticleIdList></Reference><Reference><Citation>Vig S, Lambooij JM, Dekkers MC, Otto F, Carlotti F, Guigas B, et al. . Er stress promotes mitochondrial DNA mediated type-1 interferon response in beta-cells and interleukin-8 driven neutrophil chemotaxis. Front Endocrinol (2022) 13:991632. doi:&#xa0;10.3389/fendo.2022.991632</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.991632</ArticleId><ArticleId IdType="pmc">PMC9511040</ArticleId><ArticleId IdType="pubmed">36171907</ArticleId></ArticleIdList></Reference><Reference><Citation>Colli ML, Hill JLE, Marroqui L, Chaffey J, Dos Santos RS, Leete P, et al. . Pdl1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma Via Irf1 induction. EBioMedicine (2018) 36:367&#x2013;75. doi:&#xa0;10.1016/j.ebiom.2018.09.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.09.040</ArticleId><ArticleId IdType="pmc">PMC6197434</ArticleId><ArticleId IdType="pubmed">30269996</ArticleId></ArticleIdList></Reference><Reference><Citation>Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the beta-cell (Do not blame the immune system)? Nat Rev Endocrinol (2021) 17(3):150&#x2013;61. doi:&#xa0;10.1038/s41574-020-00443-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00443-4</ArticleId><ArticleId IdType="pmc">PMC7722981</ArticleId><ArticleId IdType="pubmed">33293704</ArticleId></ArticleIdList></Reference><Reference><Citation>Guallar D, Fuentes-Iglesias A, Souto Y, Ameneiro C, Freire-Agulleiro O, Pardavila JA, et al. . Adar1-dependent rna editing promotes met and ipsc reprogramming by alleviating er stress. Cell Stem Cell (2020) 27(2):300&#x2013;14 e11. doi:&#xa0;10.1016/j.stem.2020.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.04.016</ArticleId><ArticleId IdType="pmc">PMC7415614</ArticleId><ArticleId IdType="pubmed">32396862</ArticleId></ArticleIdList></Reference><Reference><Citation>Licht K, Jantsch MF. The other face of an Editor: Adar1 functions in editing-independent ways. Bioessays (2017) 39(11):1&#x2013;6. doi:&#xa0;10.1002/bies.201700129</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.201700129</ArticleId><ArticleId IdType="pubmed">28960389</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie Y, Ding L, Kao PN, Braun R, Yang JH. Adar1 interacts with Nf90 through double-stranded rna and regulates Nf90-mediated gene expression independently of rna editing. Mol Cell Biol (2005) 25(16):6956&#x2013;63. doi:&#xa0;10.1128/MCB.25.16.6956-6963.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.16.6956-6963.2005</ArticleId><ArticleId IdType="pmc">PMC1190226</ArticleId><ArticleId IdType="pubmed">16055709</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikura K. A-to-I editing of coding and non-coding rnas by adars. Nat Rev Mol Cell Biol (2016) 17(2):83&#x2013;96. doi:&#xa0;10.1038/nrm.2015.4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2015.4</ArticleId><ArticleId IdType="pmc">PMC4824625</ArticleId><ArticleId IdType="pubmed">26648264</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghava Kurup R, Oakes EK, Manning AC, Mukherjee P, Vadlamani P, Hundley HA. Rna binding by Adar3 inhibits adenosine-to-Inosine editing and promotes expression of immune response protein mavs. J Biol Chem (2022) 298(9):102267. doi:&#xa0;10.1016/j.jbc.2022.102267</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.102267</ArticleId><ArticleId IdType="pmc">PMC9418441</ArticleId><ArticleId IdType="pubmed">35850307</ArticleId></ArticleIdList></Reference><Reference><Citation>Juan-Mateu J, Rech TH, Villate O, Lizarraga-Mollinedo E, Wendt A, Turatsinze JV, et al. . Neuron-enriched rna-binding proteins regulate pancreatic beta cell function and survival. J Biol Chem (2017) 292(8):3466&#x2013;80. doi:&#xa0;10.1074/jbc.M116.748335</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.748335</ArticleId><ArticleId IdType="pmc">PMC5336178</ArticleId><ArticleId IdType="pubmed">28077579</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkley CR, Kile BT. Cell death following the loss of Adar1 mediated a-to-I rna editing is not effected by the intrinsic apoptosis pathway. Cell Death Dis (2019) 10(12):913. doi:&#xa0;10.1038/s41419-019-2160-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-2160-6</ArticleId><ArticleId IdType="pmc">PMC6892865</ArticleId><ArticleId IdType="pubmed">31801951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>